BUZZ-Merus NV surges after cancer combo-therapy succeeds in mid-stage trial

Reuters
24 May
BUZZ-Merus NV surges after cancer combo-therapy succeeds in mid-stage trial

** U.S.-listed shares of Dutch drugmaker Merus NV MRUS.O surge 32% to $54.93

** Late on Thursday, Merus' lead drug candidate petosemtamab in combination with Merck's MRK.N Keytruda delayed progression of a type of head and neck cancer in a mid-stage trial

** The combination treatment showed a 79% survival rate after 1 year in a group of 43 patients

** Including session's moves, MRUS stock up 29.6% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10